GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Senhwa Biosciences Inc (ROCO:6492) » Definitions » Change In Receivables

Senhwa Biosciences (ROCO:6492) Change In Receivables : NT$9.99 Mil (TTM As of Dec. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Senhwa Biosciences Change In Receivables?

Senhwa Biosciences's change in receivables for the quarter that ended in Dec. 2024 was NT$10.17 Mil. It means Senhwa Biosciences's Accounts Receivable declined by NT$10.17 Mil from Sep. 2024 to Dec. 2024 .

Senhwa Biosciences's change in receivables for the fiscal year that ended in Dec. 2024 was NT$9.99 Mil. It means Senhwa Biosciences's Accounts Receivable declined by NT$9.99 Mil from Dec. 2023 to Dec. 2024 .

Senhwa Biosciences's Accounts Receivable for the quarter that ended in Dec. 2024 was NT$0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Senhwa Biosciences's Days Sales Outstanding for the three months ended in Dec. 2024 was 0.00.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Senhwa Biosciences's liquidation value for the three months ended in Dec. 2024 was NT$987.05 Mil.


Senhwa Biosciences Change In Receivables Historical Data

The historical data trend for Senhwa Biosciences's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Senhwa Biosciences Change In Receivables Chart

Senhwa Biosciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.05 -0.19 0.14 -9.87 9.99

Senhwa Biosciences Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.87 -0.35 -0.09 0.26 10.17

Senhwa Biosciences Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$9.99 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Senhwa Biosciences  (ROCO:6492) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Senhwa Biosciences's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0/0.25*91
=0.00

2. In Ben Graham's calculation of liquidation value, Senhwa Biosciences's accounts receivable are only considered to be worth 75% of book value:

Senhwa Biosciences's liquidation value for the quarter that ended in Dec. 2024 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=1025.97-38.925+0.75 * 0+0.5 * 0
=987.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Senhwa Biosciences Change In Receivables Related Terms

Thank you for viewing the detailed overview of Senhwa Biosciences's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Senhwa Biosciences Business Description

Traded in Other Exchanges
N/A
Address
Peihsin Road, 10th Floor, No. 225, Section 3, Hsintien District, New Taipei, TWN, 23143
Senhwa Biosciences Inc is engaged in the development of new drugs and special pharmaceutical ingredients focusing on human efficacy. The company's product pipeline includes Pidnarulex (CX-5461), Silmitasertib (CX-4945), and Silmitasertib (for Moderate Covid-19). All of its revenue comes from Taiwan.

Senhwa Biosciences Headlines

No Headlines